Loading…
Jyong Biotech Ltd. is projected to decline to $2.16 by 2027, a 0% move from its current price of $2.16. MENS is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $2.07 | $2.16 | $2.25 | -0.07% |
| May 30 | $2.03 | $2.16 | $2.29 | -0.14% |
| May 31 | $2.00 | $2.16 | $2.32 | -0.21% |
| Jun 1 | $1.98 | $2.15 | $2.35 | -0.28% |
| Jun 2 | $1.95 | $2.15 | $2.37 | -0.35% |
| Jun 3 | $1.94 | $2.15 | $2.39 | -0.42% |
| Jun 4 | $1.92 | $2.15 | $2.41 | -0.49% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $1.92 | $2.15 | $2.41 | -0.49% |
| Week 2 | $1.82 | $2.14 | $2.51 | -0.98% |
| Week 3 | $1.75 | $2.13 | $2.59 | -1.46% |
| Week 4 | $1.69 | $2.12 | $2.66 | -1.94% |
| Week 5 | $1.63 | $2.11 | $2.72 | -2.43% |
| Week 6 | $1.59 | $2.10 | $2.77 | -2.90% |
| Week 7 | $1.54 | $2.09 | $2.82 | -3.38% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Jyong Biotech Ltd. is a science-driven biotechnology company that develops and commercializes plant-derived drugs for the treatment of urinary system diseases in the United States, the European Union, and Asia. It develops MCS-2 for the treatment of benign prostate hyperplasia/lower urinary tract symptoms; PCP for treating prostate cancer; and interstitial cystitis (IC) for the treatment of IC/bladder pain syndrome.
The company was founded in 2002 and is headquartered in New Taipei City, Taiwan.
Jyong Biotech Ltd. trades under the symbol MENS and is currently priced at $2.15 per share. Its market cap is $163.46M and it is ranked 3970.
A major floor 32.4% below — a decisive break under it would weaken the trend.
The nearest floor, 9.7% below — buyers have tended to step in here.
The nearest ceiling, 21.8% above — a clean break opens room to run.
A major ceiling 54.2% above — clearing it would confirm fresh momentum.
Key MENS support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of MENS market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $2.15 | Buy | $2.14 | Buy |
| MA 10 | $2.10 | Buy | $2.12 | Buy |
| MA 20 | $2.11 | Buy | $2.14 | Buy |
| MA 50 | $2.19 | Sell | $2.61 | Sell |
| MA 100 | $2.38 | Sell | $6.05 | Sell |
| MA 200 | $21.83 | Sell | $11.69 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 49.84 | Neutral |
| Stoch RSI (14) | 94.86 | Sell |
| CCI (20) | 47.26 | Neutral |
| Williams %R (14) | -8.70 | Info |
| MACD (12,26,9) | 0.02 | Buy |
| ROC (12) | 5.37 | Buy |
| Bollinger %B (20,2) | 0.65 | Neutral |
| Stochastic %K (14) | 91.30 | Sell |
| TRIX (15) | -0.33 | Sell |
| Awesome (5,34) | -0.09 | Sell |
| Ultimate (7,14,28) | 57.36 | Neutral |
| Momentum (10) | 0.07 | Buy |
| Aroon Osc (25) | -72.00 | Sell |
| Hull MA (9) | 2.18 | Sell |
| ADX (14) | 10.41 | Neutral |
| ATR (14) | 0.07 | Info |
The 30-day technical picture is currently NEUTRAL with an RSI14 of 50. The price is trading near the SMA50 of $2.18, while the SMA200 sits at $22.21. The 30-day price range spans from $1.62 to $2.86, with a defined support at $1.95 and a resistance at $2.79.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $1.46 | $2.16 | $3.25 | 0% | Neutral | |
| $1.52 | $2.16 | $3.32 | 0% | Neutral | |
| $1.77 | $2.69 | $4.41 | +24% | Bullish | |
| $2.11 | $3.38 | $5.83 | +57% | Bullish | |
| $1.89 | $3.20 | $5.75 | +48% | Bullish | |
| $1.85 | $3.30 | $6.15 | +53% | Bullish | |
| $1.69 | $3.16 | $6.08 | +46% | Bullish | |
| $1.49 | $2.92 | $5.78 | +35% | Bullish | |
| $1.85 | $3.79 | $7.70 | +75% | Bullish | |
| $2.09 | $4.48 | $9.32 | +107% | Bullish | |
| $2.07 | $4.60 | $10.57 | +113% | Bullish | |
| $5.07 | $11.27 | $25.92 | +422% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $1.46 | $2.16 | $2.56 | +0.00% |
| June 2026 | $1.69 | $2.04 | $2.55 | -5.68% |
| July 2026 | $1.65 | $2.03 | $2.60 | -0.55% |
| August 2026 | $1.73 | $2.15 | $2.83 | +6.34% |
| September 2026 | $1.72 | $2.17 | $2.89 | +0.66% |
| October 2026 | $1.67 | $2.13 | $2.89 | -1.77% |
| November 2026 | $1.74 | $2.24 | $3.08 | +5.27% |
| December 2026 | $1.80 | $2.34 | $3.25 | +4.36% |
Click any year to see its month-by-month MENS forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
In 2026, MENS is projected to trade between $1.46 and $3.25, averaging $2.16 — a potential gain of 0% from today's $2.16. Price action looks broadly range-bound.
Jyong Biotech Ltd.'s 2027 outlook centres on $2.16, within a $1.52 to $3.32 range. That is 0% versus the projected 2026 average. That marks a 0% change versus current levels. A consolidation phase looks the most probable path here.
By 2028, MENS could reach as high as $4.41, with a base case around $2.69 and support toward $1.77 — roughly +24% from $2.16. Momentum favours further upside here.
Expect MENS to range from $2.11 to $5.83 through 2029. The $3.38 average target implies a +57% move from current prices. That is up +26% on the projected 2028 average. Buyers look set to stay in control over this stretch.
The MENS price prediction for 2030 points to an average of $3.20 (low $1.89, high $5.75) — a potential gain of +48% on today's $2.16. Momentum favours further upside here.
In 2031, MENS is projected to trade between $1.85 and $6.15, averaging $3.30 — a potential gain of +53% from today's $2.16. That is up +3% on the projected 2030 average. Buyers look set to stay in control over this stretch.
Jyong Biotech Ltd.'s 2032 outlook centres on $3.16, within a $1.69 to $6.08 range. That is -4% versus the projected 2031 average. That marks a +46% change versus current levels. Momentum favours further upside here.
By 2033, MENS could reach as high as $5.78, with a base case around $2.92 and support toward $1.49 — roughly +35% from $2.16. Buyers look set to stay in control over this stretch.
Expect MENS to range from $1.85 to $7.70 through 2034. The $3.79 average target implies a +75% move from current prices. That is up +30% on the projected 2033 average. Momentum favours further upside here.
The MENS price prediction for 2035 points to an average of $4.48 (low $2.09, high $9.32) — a potential gain of +107% on today's $2.16. Buyers look set to stay in control over this stretch.
In 2040, MENS is projected to trade between $2.07 and $10.57, averaging $4.60 — a potential gain of +113% from today's $2.16. That is up +3% on the projected 2035 average. Momentum favours further upside here.
Jyong Biotech Ltd.'s 2050 outlook centres on $11.27, within a $5.07 to $25.92 range. That is up +145% on the projected 2040 average. That marks a +422% change versus current levels. Buyers look set to stay in control over this stretch.
Investing $1,000 in MENS today (≈ 462.962963 MENS) could be worth
$5,216.63
+$4,216.63 (+422%) by 2050 · US Dollar
Based on the average projected MENS price of $11.27 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in MENSwould be worth at today's price.
$1,000 invested in MENS on Jun 17, 2025 (≈ 98.911972 MENS) would be worth
$213.65
-$786.35 (-78.6%) today · 0.21× · US Dollar
Based on a MENS entry price of $10.11 vs. today's $2.16.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $2.17 | $995.39 | -0.5% |
| 1 month ago | $2.15 | $1,004.65 | +0.5% |
| 3 months ago | $2.3 | $939.13 | -6.1% |
| 6 months ago | $27.2 | $79.41 | -92.1% |
| All time ago | $10.11 | $213.65 | -78.6% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our MENS forecast.
Our base-case forecast reaches $4.30 around 2035.
Implied market cap at $4.30: $319.2M
The multi-year forecast shows a bullish trajectory beginning in 2028, with 2028 average price of $2.68 (ROI 24.5) and 2029 average $3.35 (ROI 55.9), followed by 2030 average $3.14 (ROI 46.3) and 2031 average $3.27 (ROI 51.9). The path continues through 2032 at $3.11 (ROI 44.4), 2033 at $2.86 (ROI 32.9), 2034 at $3.76 (ROI 74.8), and 2035 at $4.38 (ROI 104). The outlook extends to 2040 with an average of $4.56 (ROI 112.2) and culminates in 2050 with an average of $10.98 (ROI 410.7).
The sentiment shifts to BULLISH across these long-horizon years.
Tap a question to reveal the answer.
In 2030 the forecast shows min $1.85, avg $3.14, max $5.68 with ROI 46.3 and sentiment BULLISH.
The forecast turns bullish from 2028 onward with rising averages and positive ROI in several years (e.g., 2028 ROI 24.5, 2029 ROI 55.9, 2030 ROI 46.3, 2031 ROI 51.9). The 2050 outlook shows avg $10.98 and max $25.26 with ROI 410.7, though some prior years show flat or negative ROI (e.g., 2027 ROI -1.3). These are estimates, not guarantees.
Yes. The 2050 forecast lists a max of $25.26, with an average of $10.98 and ROI 410.7.
Current price is $2.15 and the market cap is $163.46M.
The 30-day picture shows NEUTRAL sentiment, RSI 50, SMA50 of $2.18, and SMA200 of $22.21. The 30-day range is $1.62 to $2.86, with support at $1.95 and resistance at $2.79.
Jyong Biotech Ltd. Community Discussion
0Share your Jyong Biotech Ltd. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.